Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib versus platinum-based adjuvant chemotherapy after complete resection of ALK-positive NSCLC
MOH_2018-08-02_002419Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Disease-free survival. Started Jul 2018; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2018-08-02_002419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-02_002419.